Background: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept (ABA) than anti-CCP negativity in patients (pts) with RA 1,2 ; however, there are no head-to-head or comparative effectiveness research studies available evaluating responses to biologics in CCP+ pts in a real-world setting. Objectives: To compare the effectiveness of ABA vs a TNF inhibitor (TNFi) in pts with RA who are CCP+. Methods: We identified adult pts with RA from a large observational US cohort (1 Dec 2005-31 Aug 2016) who initiated ABA or a TNFi and who were CCP+ (≥20 U/mL) at or prior to initiation. Both groups had to have no prior exposure to other non-TNFi biologics or targeted synthetic DMARDs. TNFi initiators were excluded if they had prior use of ABA. Using propensity score matching (1:1) stratified by prior TNFi use (0, 1 and 2+), effectiveness at 6 months after initiation was evaluated. Mean change in CDAI over 6 months following initiation was the primary outcome, and secondary outcomes were: achievement of remission (CDAI ≤2.8), modified (m)ACR20, 50 and 70 responses and achievement of LDA/remission (CDAI ≤10) in those with moderate/high disease activity at initiation. A subset analysis was performed to consider separately pts who were biologic naïve and those who were biologic experienced at initiation.
Results: The 330 pairs of propensity score-matched ABA and TNFi initiators had no substantial differences in baseline characteristics. Both treatment groups had similar mean change in CDAI at 6 months as well as achievement of LDA, remission and mACR20/50/70 responses (Table) . Among the 97 matched biologic-naïve pairs, there was no significant difference in change in CDAI for ABA initiators vs TNFi initiators (p=0.19). However, in the 233 matched biologicexperienced pairs, those initiating ABA had a greater improvement in mean change in CDAI (p=0.033) and were more likely to achieve an mACR50 response (p=0.014).
Conclusions:
Pts with RA who were CCP+ and received either ABA or TNFi had a substantial improvement in clinical disease activity. In the overall propensity score-matched sample, similar outcomes were observed for both treatment groups. However, analysis of the biologic-experienced cohort found that ABA initiators had a greater improvement in disease activity than TNFi initiators. Background: Tocilizumab (TCZ) is a monoclonal antibody directed against the IL-6 receptors. This treatment (TRT) allows for the cortisone weaning in preventing of its complications. Objectives: The goal of this study is to evaluate the corticosteroid sparing in patients with RA treated with TCZ. Methods: Prospective, descriptive study of patients hospitalized between 2012 and 2016, the diagnosis was made according to the ACR 1987 ACR/EULAR 2010 criteria. Included, are the patients treated with TCZ for at least 3 months associated with corticosteroids. We have studied the following: the epidemiology, the associated DMARDs, the average DAS28VS, the average dosage of prednisone-equivalent and the percentage of patients with decreased or interrupted corticosteroids at M0, M3, M6 and M12. Results: 26 patients (sex ratio: 0.7) treated with TCZ and corticosteroids, average age is 43.4 years (range 30-62). Average duration of the development of RA: 9.1±6.4 years. DMARDs was associated in 15 patient. At baseline, 46.2% of patients were on 10 mg/day of cortisone, the average dose of prednisone-equivalent was at 7.7±3.6mg at M0, 5.3±3.2 mg at M3, 4.6±2.3 mg at M6, 2.6±2.6 mg at M12 with a statistically significant difference (p=0.000003). The average DASVS28 activity index was 5.6±0.9 at M0, 3.5±1.3 at M3, 3.04±1.2 at M6 and 2.6 ± M6 at M12 with a statistically significant difference (p<0.000001).
Corticosteroid treatment was stopped in 12 patients after 1 year of treatment.
Conclusions: Through this study we note that the TRT using TCZ has enabled a significant reduction in the dose of corticosteroids. Stopping prednisone was possible in 50% of patients after 1 year of biotherapy. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.3965
